BACKGROUND: Patients with follicular lymphoma may survive for periods of less than 1 year to more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop a molecular predictor of the length of survival. METHODS: Gene-expression profiling was performed on 191 biopsy specimens obtained from patients with untreated follicular lymphoma. Supervised methods were used to discover expression patterns associated with the length of survival in a training set of 95 specimens. A molecular predictor of survival was constructed from these genes and validated in an independent test set of 96 specimens. RESULTS: Individual genes that predicted the length of survival were grouped into gene-expression signatures on the basis of their expression in the training set, and two such signatures were used to construct a survival predictor. The two signatures allowed patients with specimens in the test set to be divided into four quartiles with widely disparate median lengths of survival (13.6, 11.1, 10.8, and 3.9 years), independently of clinical prognostic variables. Flow cytometry showed that these signatures reflected gene expression by nonmalignant tumor-infiltrating immune cells. CONCLUSIONS: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis. Copyright 2004 Massachusetts Medical Society.
BACKGROUND:Patients with follicular lymphoma may survive for periods of less than 1 year to more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop a molecular predictor of the length of survival. METHODS: Gene-expression profiling was performed on 191 biopsy specimens obtained from patients with untreated follicular lymphoma. Supervised methods were used to discover expression patterns associated with the length of survival in a training set of 95 specimens. A molecular predictor of survival was constructed from these genes and validated in an independent test set of 96 specimens. RESULTS: Individual genes that predicted the length of survival were grouped into gene-expression signatures on the basis of their expression in the training set, and two such signatures were used to construct a survival predictor. The two signatures allowed patients with specimens in the test set to be divided into four quartiles with widely disparate median lengths of survival (13.6, 11.1, 10.8, and 3.9 years), independently of clinical prognostic variables. Flow cytometry showed that these signatures reflected gene expression by nonmalignant tumor-infiltrating immune cells. CONCLUSIONS: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis. Copyright 2004 Massachusetts Medical Society.
Authors: P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte Journal: Leukemia Date: 2011-10-21 Impact factor: 11.528
Authors: Beatriz Sánchez-Espiridión; Ana M Martin-Moreno; Carlos Montalbán; L Jeffrey Medeiros; Francisco Vega; Anas Younes; Miguel A Piris; Juan F Garcia Journal: Haematologica Date: 2012-02-07 Impact factor: 9.941
Authors: Javeed Iqbal; Yulei Shen; Yanyan Liu; Kai Fu; Elaine S Jaffe; Cuiling Liu; Zhongfeng Liu; Cynthia M Lachel; Karen Deffenbacher; Timothy C Greiner; Julie M Vose; Sharathkumar Bhagavathi; Louis M Staudt; Lisa Rimsza; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Timothy W McKeithan; Wing C Chan Journal: Blood Date: 2012-04-05 Impact factor: 22.113
Authors: Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust Journal: Clin Cancer Res Date: 2017-12-07 Impact factor: 12.531
Authors: Kui Shin Voo; Myriam Foglietta; Elena Percivalle; Fuliang Chu; Durga Nattamai; Megan Harline; Seung-Tae Lee; Laura Bover; Heather Y Lin; Veerabhadran Baladandayuthapani; David Delgado; Amber Luong; R Eric Davis; Larry W Kwak; Yong-Jun Liu; Sattva S Neelapu Journal: Int J Cancer Date: 2014-05-12 Impact factor: 7.396
Authors: Anne Tuomisto; Malin Sund; Jenni Tahkola; Anne Latvanlehto; Eeva-Riitta Savolainen; Helena Autio-Harmainen; Annikki Liakka; Raija Sormunen; Jussi Vuoristo; Anne West; Riitta Lahesmaa; Herbert C Morse; Taina Pihlajaniemi Journal: Cancer Res Date: 2008-12-15 Impact factor: 12.701
Authors: Hongxiu Li; Mark S Kaminski; Yifeng Li; Mehmet Yildiz; Peter Ouillette; Siân Jones; Heather Fox; Kathryn Jacobi; Kamlai Saiya-Cork; Dale Bixby; Daniel Lebovic; Diane Roulston; Kerby Shedden; Michael Sabel; Lawrence Marentette; Vincent Cimmino; Alfred E Chang; Sami N Malek Journal: Blood Date: 2014-01-16 Impact factor: 22.113
Authors: Tint Lwin; Xiaohong Zhao; Fengdong Cheng; Xinwei Zhang; Andy Huang; Bijal Shah; Yizhuo Zhang; Lynn C Moscinski; Yong Sung Choi; Alan P Kozikowski; James E Bradner; William S Dalton; Eduardo Sotomayor; Jianguo Tao Journal: J Clin Invest Date: 2013-11 Impact factor: 14.808